#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucopolysaccharidosis I Desmoplastic small round cell tumour C3 glomerulopathy Immunodeficiency common variable General anaesthesia Lymphangioma Transitional cell cancer of the renal pelvis and ureter Salivary gland cancer Burkitt's lymphoma Non-Hodgkin's lymphoma unspecified histology indolent VEXAS syndrome Cholangitis sclerosing Myeloid leukaemia Hypersomnia Hypersensitivity pneumonitis More trials…

    Learn about Rare Diseases

    Primary hyperoxaluria – Basic Information Hereditary angioedema with C1 esterase inhibitor deficiency Lymphangiosarcoma – Life with Disease Bronchiolitis obliterans syndrome – Treatment Waldenstrom’s macroglobulinaemia refractory – Diagnostics Mantle cell lymphoma stage III – Treatment Congenital generalised lipodystrophy – Life with Disease Brain stem glioma – Life with Disease Mast cell activation syndrome – Diagnostics Haemophilia B without inhibitors – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Diphenhydramine Hydrochloride Birtamimab Tildacerfont Timrepigene Emparvovec Tinzaparin Fluorodopa (18F) Gozetotide Alf-18 For-6219 Amb-05X Fludeoxyglucose (18F) Dog Epithelium Extract Lisdexamfetamine Dimesylate Gallium (68Ga) SODIUM BENZOATE ALPROSTADIL Nemolizumab Imipenem Ribonucleic Acid K30 Valproic Acid GXV813 More therapies…

    Learn about Your Condition

    Endocrine disorder Aplastic anaemia Pulmonary tuberculosis Low cardiac output syndrome Pulmonary fibrosis Endometrial cancer stage III Pemphigoid Papillary thyroid cancer Tendon injury Thymoma malignant Hypersensitivity Retinopathy proliferative Cerebrovascular accident Chronic myeloid leukaemia Muscle injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cyprus

  • Study on Ketamine to Prevent Relapse in Patients with Opioid Use Disorder

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Ketamine
    Cyprus

  • Study on Improving Quality of Life for Early Breast Cancer Patients Using Duloxetine and Furosemide to Manage Endocrine Therapy-Related Pain

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Amiloride Hydrochloride
    • Furosemide
    • Duloxetine
    Cyprus France Poland Slovenia Spain

  • Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Belgium Cyprus Czechia Denmark Finland +9

  • Study on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • 18F-Psma-1007
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Cyprus The Netherlands

  • Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

    Not recruiting

    4 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Belgium Bulgaria Cyprus Czechia Denmark +13

  • Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Cyprus Czechia Denmark Finland France +9
Previous Page
1 2 3
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Efgartigimod Alfa Vutrisiran Tamoxifen Paracetamol Goserelin Epirubicin Hydrochloride Hydrocortisone Eplontersen Dacarbazine Methylprednisolone 18F-Psma-1007 Doxorubicin Hydrochloride Dexamethasone Lutetium (177Lu) Vipivotide Tetraxetan Ifosfamide Methotrexate Amiloride Hydrochloride Abatacept Mycophenolate Mofetil Furosemide Betamethasone Mycophenolic Acid Elacestrant Duloxetine Leflunomide Prednisolone Anastrozole Ketamine Hydroxychloroquine Sulfate Tacrolimus Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Back pain Cardiac amyloidosis COVID-19 Dedifferentiated liposarcoma Drug use disorder Hereditary neuropathic amyloidosis Hormone receptor positive HER2 negative breast cancer Hormone-dependent prostate cancer Idiopathic inflammatory myopathy Leiomyosarcoma Myasthenia gravis Neoplasm Ocular myasthenia Polyneuropathy Prostate cancer

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!